Neurocrine Biosciences Stock Today
| NBIX Stock | USD 138.97 1.12 0.80% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Neurocrine Biosciences is trading at 138.97 as of the 24th of April 2024; that is -0.8 percent down since the beginning of the trading day. The stock's open price was 140.09. Neurocrine Biosciences has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Neurocrine Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of March 2024 and ending today, the 24th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of May 1996 | Category Healthcare | Classification Health Care |
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California. Neurocrine Bioscienc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 100.58 M outstanding shares of which 2.43 M shares are now shorted by private and institutional investors with about 2.38 trading days to cover. More on Neurocrine Biosciences
Neurocrine Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Neurocrine Biosciences' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Neurocrine Biosciences or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO and President and Director | Kevin Gorman | ||||
| Thematic Idea | Obamacare Repeal (View all Themes) | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, ARCA Biotechnology, SP Midcap 400, Dow Jones Biotechnology, NASDAQ Composite Total, NASDAQ Health Care, Obamacare Repeal, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation Analysts covering Neurocrine Biosciences report their recommendations after researching Neurocrine Biosciences' financial statements, talking to executives and customers, or listening in on Neurocrine Biosciences' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Neurocrine Biosciences. The Neurocrine consensus assessment is calculated by taking the average forecast from all of the analysts covering Neurocrine Biosciences. | |||||
Neurocrine Biosciences' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Neurocrine Biosciences' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Neurocrine Biosciences' financial leverage. It provides some insight into what part of Neurocrine Biosciences' total assets is financed by creditors.
| |||||
Neurocrine Biosciences (NBIX) is traded on NASDAQ Exchange in USA. It is located in 12780 El Camino Real, San Diego, CA, United States, 92130 and employs 1,400 people. Neurocrine Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 14.09 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Neurocrine Biosciences's market, we take the total number of its shares issued and multiply it by Neurocrine Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Neurocrine Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 100.58 M outstanding shares of which 2.43 M shares are now shorted by private and institutional investors with about 2.38 trading days to cover.
Neurocrine Biosciences currently holds about 799.4 M in cash with 389.9 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.31.
Check Neurocrine Biosciences Probability Of Bankruptcy
Ownership AllocationNeurocrine Biosciences holds a total of 100.58 Million outstanding shares. The majority of Neurocrine Biosciences outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Neurocrine Biosciences to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Neurocrine Biosciences. Please pay attention to any change in the institutional holdings of Neurocrine Biosciences as this could imply that something significant has changed or is about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check Neurocrine Ownership Details
Neurocrine Stock Price Odds Analysis
Based on a normal probability distribution, the odds of Neurocrine Biosciences jumping above the current price in 90 days from now is about 30.99%. The Neurocrine Biosciences probability density function shows the probability of Neurocrine Biosciences stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Neurocrine Biosciences has a beta of 0.5382. This indicates as returns on the market go up, Neurocrine Biosciences average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Neurocrine Biosciences will be expected to be much smaller as well. Additionally, neurocrine Biosciences has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Neurocrine Biosciences to move above the current price in 90 days from now is about 30.99 (This Neurocrine Biosciences probability density function shows the probability of Neurocrine Stock to fall within a particular range of prices over 90 days) .
Neurocrine Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Neurocrine Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Neurocrine Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Neurocrine Biosciences' value.| Instituion | Recorded On | Shares | |
| Goldman Sachs Group Inc | 2023-12-31 | 1.4 M | |
| Dodge & Cox | 2023-12-31 | 1.3 M | |
| Dsm Capital Partners Llc | 2023-12-31 | 1.2 M | |
| Pictet Asset Manangement Sa | 2023-12-31 | 1.2 M | |
| Deerfield Management Co | 2023-09-30 | 1.2 M | |
| Wellington Management Company Llp | 2023-12-31 | 1.2 M | |
| Rock Springs Capital Management Lp | 2023-12-31 | 1.2 M | |
| Brown Advisory Holdings Inc | 2023-12-31 | 1.1 M | |
| Armistice Capital, Llc | 2023-12-31 | 1 M | |
| Blackrock Inc | 2023-12-31 | 13.6 M | |
| Vanguard Group Inc | 2023-12-31 | 9.7 M |
Neurocrine Biosciences Historical Income Statement
Neurocrine Biosciences Income Statement is one of the three primary financial statements used for reporting Neurocrine's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Neurocrine Biosciences revenue and expense. Neurocrine Biosciences Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Neurocrine Biosciences' Total Operating Expenses is fairly stable compared to the past year. Income Before Tax is likely to rise to about 348.7 M in 2024, whereas Cost Of Revenue is likely to drop slightly above 38.9 M in 2024. View More FundamentalsNeurocrine Stock Against Markets
Picking the right benchmark for Neurocrine Biosciences stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Neurocrine Biosciences stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Neurocrine Biosciences is critical whether you are bullish or bearish towards Neurocrine Biosciences at a given time. Please also check how Neurocrine Biosciences' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Neurocrine Biosciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Manager Now
Portfolio ManagerState of the art Portfolio Manager to monitor and improve performance of your invested capital |
| All Next | Launch Module |
Neurocrine Biosciences Corporate Directors
Neurocrine Biosciences corporate directors refer to members of a Neurocrine Biosciences board of directors. The board of directors generally takes responsibility for the Neurocrine Biosciences' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Neurocrine Biosciences' board members must vote for the resolution. The Neurocrine Biosciences board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Joseph Mollica | Independent Director | Profile | |
| George Morrow | Director | Profile | |
| Richard Pops | Independent Director | Profile | |
| Alfred Sandrock | Director | Profile |
How to buy Neurocrine Stock?
Before investing in Neurocrine Biosciences, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Neurocrine Biosciences. To buy Neurocrine Biosciences stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Neurocrine Biosciences. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Neurocrine Biosciences stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Neurocrine Biosciences stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Neurocrine Biosciences stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Neurocrine Biosciences, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.
Already Invested in Neurocrine Biosciences?
The danger of trading Neurocrine Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Neurocrine Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Neurocrine Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Neurocrine Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Neurocrine Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurocrine Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurocrine Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurocrine Biosciences Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for Neurocrine Stock analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Stocks Directory Find actively traded stocks across global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |
Is Neurocrine Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurocrine Biosciences. If investors know Neurocrine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurocrine Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.648 | Earnings Share 2.47 | Revenue Per Share 19.315 | Quarterly Revenue Growth 0.25 | Return On Assets 0.0878 |
The market value of Neurocrine Biosciences is measured differently than its book value, which is the value of Neurocrine that is recorded on the company's balance sheet. Investors also form their own opinion of Neurocrine Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Neurocrine Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurocrine Biosciences' market value can be influenced by many factors that don't directly affect Neurocrine Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurocrine Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurocrine Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurocrine Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.